Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study

To investigate whether intraocular pressure (IOP) fluctuation is associated independently with the rate of visual field (VF) progression in the United Kingdom Glaucoma Treatment Study. Randomized, double-masked, placebo-controlled multicenter trial. Participants with ≥5 VFs (213 placebo, 217 treatme...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ophthalmology (Rochester, Minn.) Minn.), 2024-08, Vol.131 (8), p.902-913
Hauptverfasser: Rabiolo, Alessandro, Montesano, Giovanni, Crabb, David P., Garway-Heath, David F., Bunce, Catey, Lascaratos, Gerassimos, Amalfitano, Francesca, Anand, Nitin, Azuara-Blanco, Augusto, Bourne, Rupert R., Broadway, David C., Cunliffe, Ian A., Diamond, Jeremy P., Fraser, Scott G., Ho, Tuan A., Martin, Keith R., McNaught, Andrew I., Negi, Anil, Patel, Krishna, Russell, Richard A., Shah, Ameet, Spry, Paul G., Suzuki, Katsuyoshi, White, Edward T., Wormald, Richard P., Xing, Wen, Zeyen, Thierry G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 913
container_issue 8
container_start_page 902
container_title Ophthalmology (Rochester, Minn.)
container_volume 131
creator Rabiolo, Alessandro
Montesano, Giovanni
Crabb, David P.
Garway-Heath, David F.
Garway-Heath, David F.
Crabb, David P.
Bunce, Catey
Lascaratos, Gerassimos
Amalfitano, Francesca
Anand, Nitin
Azuara-Blanco, Augusto
Bourne, Rupert R.
Broadway, David C.
Cunliffe, Ian A.
Diamond, Jeremy P.
Fraser, Scott G.
Ho, Tuan A.
Martin, Keith R.
McNaught, Andrew I.
Negi, Anil
Patel, Krishna
Russell, Richard A.
Shah, Ameet
Spry, Paul G.
Suzuki, Katsuyoshi
White, Edward T.
Wormald, Richard P.
Xing, Wen
Zeyen, Thierry G.
description To investigate whether intraocular pressure (IOP) fluctuation is associated independently with the rate of visual field (VF) progression in the United Kingdom Glaucoma Treatment Study. Randomized, double-masked, placebo-controlled multicenter trial. Participants with ≥5 VFs (213 placebo, 217 treatment). Associations between IOP metrics and VF progression rates (mean deviation [MD] and five fastest locations) were assessed with linear mixed models. Fluctuation variables were mean Pascal ocular pulse amplitude (OPA), standard deviation (SD) of diurnal Goldmann IOP (diurnal fluctuation), and SD of Goldmann IOP at all visits (long-term fluctuation). Fluctuation values were normalized for mean IOP to make them independent from the mean IOP. Correlated nonfluctuation IOP metrics (baseline, peak, mean, supine, and peak phasing IOP) were combined with principal component analysis, and principal component 1 (PC1) was included as a covariate. Interactions between covariates and time from baseline modeled the effect of the variables on VF rates. Analyses were conducted separately in the two treatment arms. Associations between IOP fluctuation metrics and rates of MD and the five fastest test locations. In the placebo arm, only PC1 was associated significantly with the MD rate (estimate, –0.19 dB/year [standard error (SE), 0.04 dB/year]; P < 0.001), whereas normalized IOP fluctuation metrics were not. No variable was associated significantly with MD rates in the treatment arm. For the fastest five locations in the placebo group, PC1 (estimate, –0.58 dB/year [SE, 0.16 dB/year]; P < 0.001), central corneal thickness (estimate, 0.26 dB/year [SE, 0.10 dB/year] for 10 μm thicker; P = 0.01) and normalized OPA (estimate, –3.50 dB/year [SE, 1.04 dB/year]; P = 0.001) were associated with rates of progression; normalized diurnal and long-term IOP fluctuations were not. In the treatment group, only PC1 (estimate, –0.27 dB/year [SE, 0.12 dB/year]; P = 0.028) was associated with the rates of progression. No evidence supports that either diurnal or long-term IOP fluctuation, as measured in clinical practice, are independent factors for glaucoma progression; other aspects of IOP, including mean IOP and peak IOP, may be more informative. Ocular pulse amplitude may be an independent factor for faster glaucoma progression. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
doi_str_mv 10.1016/j.ophtha.2024.02.008
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2927214209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0161642024001234</els_id><sourcerecordid>2927214209</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-878afa7d071858f6beadf0226b3a67628972c568dada1346d28599642c48a05d3</originalsourceid><addsrcrecordid>eNp90c1u1DAUBWALgei08AYIeckmwXYSx9kgoapTqlYClZatdce-6XiUxIN_QH0CXhsPU1iy8sLf9ZXPIeQNZzVnXL7f1X6_TVuoBRNtzUTNmHpGVrxrh6rtefOcrArjlWwFOyGnMe4YY1I27Uty0qimMM5X5NctTpCcX-LW7ekG00_EhV4tKYA3eYJAvwSMMQek6ymblP9gCoul31zMMNG1w8kW5R8O8HB5CwkjdQtNW6T3i0to6bVbHqyf6eUE2fgZ6F1ASDMuiX5N2T6-Ii9GmCK-fjrPyP364u78U3Xz-fLq_ONNZVqmUqV6BSP0lvVcdWqUGwQ7MiHkpgHZS6GGXphOKgsWeNNKK1Q3DCUC0ypgnW3OyLvju_vgv2eMSc8uGpwmWNDnqMUgesFLZEOh7ZGa4GMMOOp9cDOER82ZPlSgd_pYgT5UoJnQpYIy9vZpQ97MaP8N_c28gA9HgOWfPxwGHY3DxaB1AU3S1rv_b_gNoEyboA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2927214209</pqid></control><display><type>article</type><title>Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Rabiolo, Alessandro ; Montesano, Giovanni ; Crabb, David P. ; Garway-Heath, David F. ; Garway-Heath, David F. ; Crabb, David P. ; Bunce, Catey ; Lascaratos, Gerassimos ; Amalfitano, Francesca ; Anand, Nitin ; Azuara-Blanco, Augusto ; Bourne, Rupert R. ; Broadway, David C. ; Cunliffe, Ian A. ; Diamond, Jeremy P. ; Fraser, Scott G. ; Ho, Tuan A. ; Martin, Keith R. ; McNaught, Andrew I. ; Negi, Anil ; Patel, Krishna ; Russell, Richard A. ; Shah, Ameet ; Spry, Paul G. ; Suzuki, Katsuyoshi ; White, Edward T. ; Wormald, Richard P. ; Xing, Wen ; Zeyen, Thierry G.</creator><creatorcontrib>Rabiolo, Alessandro ; Montesano, Giovanni ; Crabb, David P. ; Garway-Heath, David F. ; Garway-Heath, David F. ; Crabb, David P. ; Bunce, Catey ; Lascaratos, Gerassimos ; Amalfitano, Francesca ; Anand, Nitin ; Azuara-Blanco, Augusto ; Bourne, Rupert R. ; Broadway, David C. ; Cunliffe, Ian A. ; Diamond, Jeremy P. ; Fraser, Scott G. ; Ho, Tuan A. ; Martin, Keith R. ; McNaught, Andrew I. ; Negi, Anil ; Patel, Krishna ; Russell, Richard A. ; Shah, Ameet ; Spry, Paul G. ; Suzuki, Katsuyoshi ; White, Edward T. ; Wormald, Richard P. ; Xing, Wen ; Zeyen, Thierry G. ; United Kingdom Glaucoma Treatment Study Investigators</creatorcontrib><description>To investigate whether intraocular pressure (IOP) fluctuation is associated independently with the rate of visual field (VF) progression in the United Kingdom Glaucoma Treatment Study. Randomized, double-masked, placebo-controlled multicenter trial. Participants with ≥5 VFs (213 placebo, 217 treatment). Associations between IOP metrics and VF progression rates (mean deviation [MD] and five fastest locations) were assessed with linear mixed models. Fluctuation variables were mean Pascal ocular pulse amplitude (OPA), standard deviation (SD) of diurnal Goldmann IOP (diurnal fluctuation), and SD of Goldmann IOP at all visits (long-term fluctuation). Fluctuation values were normalized for mean IOP to make them independent from the mean IOP. Correlated nonfluctuation IOP metrics (baseline, peak, mean, supine, and peak phasing IOP) were combined with principal component analysis, and principal component 1 (PC1) was included as a covariate. Interactions between covariates and time from baseline modeled the effect of the variables on VF rates. Analyses were conducted separately in the two treatment arms. Associations between IOP fluctuation metrics and rates of MD and the five fastest test locations. In the placebo arm, only PC1 was associated significantly with the MD rate (estimate, –0.19 dB/year [standard error (SE), 0.04 dB/year]; P &lt; 0.001), whereas normalized IOP fluctuation metrics were not. No variable was associated significantly with MD rates in the treatment arm. For the fastest five locations in the placebo group, PC1 (estimate, –0.58 dB/year [SE, 0.16 dB/year]; P &lt; 0.001), central corneal thickness (estimate, 0.26 dB/year [SE, 0.10 dB/year] for 10 μm thicker; P = 0.01) and normalized OPA (estimate, –3.50 dB/year [SE, 1.04 dB/year]; P = 0.001) were associated with rates of progression; normalized diurnal and long-term IOP fluctuations were not. In the treatment group, only PC1 (estimate, –0.27 dB/year [SE, 0.12 dB/year]; P = 0.028) was associated with the rates of progression. No evidence supports that either diurnal or long-term IOP fluctuation, as measured in clinical practice, are independent factors for glaucoma progression; other aspects of IOP, including mean IOP and peak IOP, may be more informative. Ocular pulse amplitude may be an independent factor for faster glaucoma progression. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</description><identifier>ISSN: 0161-6420</identifier><identifier>ISSN: 1549-4713</identifier><identifier>EISSN: 1549-4713</identifier><identifier>DOI: 10.1016/j.ophtha.2024.02.008</identifier><identifier>PMID: 38354911</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Antihypertensive Agents - therapeutic use ; Circadian Rhythm - physiology ; Disease Progression ; Double-Blind Method ; Female ; Glaucoma, Open-Angle - drug therapy ; Glaucoma, Open-Angle - physiopathology ; Humans ; Intraocular Pressure - physiology ; Latanoprost - therapeutic use ; Linear mixed models ; Male ; Middle Aged ; Ocular pulse amplitude ; Risk factors ; Tonometry, Ocular ; United Kingdom ; Vision Disorders - physiopathology ; Visual field progression ; Visual Field Tests ; Visual Fields - physiology</subject><ispartof>Ophthalmology (Rochester, Minn.), 2024-08, Vol.131 (8), p.902-913</ispartof><rights>2024 American Academy of Ophthalmology</rights><rights>Copyright © 2024 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-878afa7d071858f6beadf0226b3a67628972c568dada1346d28599642c48a05d3</citedby><cites>FETCH-LOGICAL-c408t-878afa7d071858f6beadf0226b3a67628972c568dada1346d28599642c48a05d3</cites><orcidid>0000-0002-9148-2804 ; 0000-0002-7772-5929 ; 0000-0001-8754-3902</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0161642024001234$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38354911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rabiolo, Alessandro</creatorcontrib><creatorcontrib>Montesano, Giovanni</creatorcontrib><creatorcontrib>Crabb, David P.</creatorcontrib><creatorcontrib>Garway-Heath, David F.</creatorcontrib><creatorcontrib>Garway-Heath, David F.</creatorcontrib><creatorcontrib>Crabb, David P.</creatorcontrib><creatorcontrib>Bunce, Catey</creatorcontrib><creatorcontrib>Lascaratos, Gerassimos</creatorcontrib><creatorcontrib>Amalfitano, Francesca</creatorcontrib><creatorcontrib>Anand, Nitin</creatorcontrib><creatorcontrib>Azuara-Blanco, Augusto</creatorcontrib><creatorcontrib>Bourne, Rupert R.</creatorcontrib><creatorcontrib>Broadway, David C.</creatorcontrib><creatorcontrib>Cunliffe, Ian A.</creatorcontrib><creatorcontrib>Diamond, Jeremy P.</creatorcontrib><creatorcontrib>Fraser, Scott G.</creatorcontrib><creatorcontrib>Ho, Tuan A.</creatorcontrib><creatorcontrib>Martin, Keith R.</creatorcontrib><creatorcontrib>McNaught, Andrew I.</creatorcontrib><creatorcontrib>Negi, Anil</creatorcontrib><creatorcontrib>Patel, Krishna</creatorcontrib><creatorcontrib>Russell, Richard A.</creatorcontrib><creatorcontrib>Shah, Ameet</creatorcontrib><creatorcontrib>Spry, Paul G.</creatorcontrib><creatorcontrib>Suzuki, Katsuyoshi</creatorcontrib><creatorcontrib>White, Edward T.</creatorcontrib><creatorcontrib>Wormald, Richard P.</creatorcontrib><creatorcontrib>Xing, Wen</creatorcontrib><creatorcontrib>Zeyen, Thierry G.</creatorcontrib><creatorcontrib>United Kingdom Glaucoma Treatment Study Investigators</creatorcontrib><title>Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study</title><title>Ophthalmology (Rochester, Minn.)</title><addtitle>Ophthalmology</addtitle><description>To investigate whether intraocular pressure (IOP) fluctuation is associated independently with the rate of visual field (VF) progression in the United Kingdom Glaucoma Treatment Study. Randomized, double-masked, placebo-controlled multicenter trial. Participants with ≥5 VFs (213 placebo, 217 treatment). Associations between IOP metrics and VF progression rates (mean deviation [MD] and five fastest locations) were assessed with linear mixed models. Fluctuation variables were mean Pascal ocular pulse amplitude (OPA), standard deviation (SD) of diurnal Goldmann IOP (diurnal fluctuation), and SD of Goldmann IOP at all visits (long-term fluctuation). Fluctuation values were normalized for mean IOP to make them independent from the mean IOP. Correlated nonfluctuation IOP metrics (baseline, peak, mean, supine, and peak phasing IOP) were combined with principal component analysis, and principal component 1 (PC1) was included as a covariate. Interactions between covariates and time from baseline modeled the effect of the variables on VF rates. Analyses were conducted separately in the two treatment arms. Associations between IOP fluctuation metrics and rates of MD and the five fastest test locations. In the placebo arm, only PC1 was associated significantly with the MD rate (estimate, –0.19 dB/year [standard error (SE), 0.04 dB/year]; P &lt; 0.001), whereas normalized IOP fluctuation metrics were not. No variable was associated significantly with MD rates in the treatment arm. For the fastest five locations in the placebo group, PC1 (estimate, –0.58 dB/year [SE, 0.16 dB/year]; P &lt; 0.001), central corneal thickness (estimate, 0.26 dB/year [SE, 0.10 dB/year] for 10 μm thicker; P = 0.01) and normalized OPA (estimate, –3.50 dB/year [SE, 1.04 dB/year]; P = 0.001) were associated with rates of progression; normalized diurnal and long-term IOP fluctuations were not. In the treatment group, only PC1 (estimate, –0.27 dB/year [SE, 0.12 dB/year]; P = 0.028) was associated with the rates of progression. No evidence supports that either diurnal or long-term IOP fluctuation, as measured in clinical practice, are independent factors for glaucoma progression; other aspects of IOP, including mean IOP and peak IOP, may be more informative. Ocular pulse amplitude may be an independent factor for faster glaucoma progression. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</description><subject>Aged</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Circadian Rhythm - physiology</subject><subject>Disease Progression</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Glaucoma, Open-Angle - drug therapy</subject><subject>Glaucoma, Open-Angle - physiopathology</subject><subject>Humans</subject><subject>Intraocular Pressure - physiology</subject><subject>Latanoprost - therapeutic use</subject><subject>Linear mixed models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ocular pulse amplitude</subject><subject>Risk factors</subject><subject>Tonometry, Ocular</subject><subject>United Kingdom</subject><subject>Vision Disorders - physiopathology</subject><subject>Visual field progression</subject><subject>Visual Field Tests</subject><subject>Visual Fields - physiology</subject><issn>0161-6420</issn><issn>1549-4713</issn><issn>1549-4713</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90c1u1DAUBWALgei08AYIeckmwXYSx9kgoapTqlYClZatdce-6XiUxIN_QH0CXhsPU1iy8sLf9ZXPIeQNZzVnXL7f1X6_TVuoBRNtzUTNmHpGVrxrh6rtefOcrArjlWwFOyGnMe4YY1I27Uty0qimMM5X5NctTpCcX-LW7ekG00_EhV4tKYA3eYJAvwSMMQek6ymblP9gCoul31zMMNG1w8kW5R8O8HB5CwkjdQtNW6T3i0to6bVbHqyf6eUE2fgZ6F1ASDMuiX5N2T6-Ii9GmCK-fjrPyP364u78U3Xz-fLq_ONNZVqmUqV6BSP0lvVcdWqUGwQ7MiHkpgHZS6GGXphOKgsWeNNKK1Q3DCUC0ypgnW3OyLvju_vgv2eMSc8uGpwmWNDnqMUgesFLZEOh7ZGa4GMMOOp9cDOER82ZPlSgd_pYgT5UoJnQpYIy9vZpQ97MaP8N_c28gA9HgOWfPxwGHY3DxaB1AU3S1rv_b_gNoEyboA</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Rabiolo, Alessandro</creator><creator>Montesano, Giovanni</creator><creator>Crabb, David P.</creator><creator>Garway-Heath, David F.</creator><creator>Garway-Heath, David F.</creator><creator>Crabb, David P.</creator><creator>Bunce, Catey</creator><creator>Lascaratos, Gerassimos</creator><creator>Amalfitano, Francesca</creator><creator>Anand, Nitin</creator><creator>Azuara-Blanco, Augusto</creator><creator>Bourne, Rupert R.</creator><creator>Broadway, David C.</creator><creator>Cunliffe, Ian A.</creator><creator>Diamond, Jeremy P.</creator><creator>Fraser, Scott G.</creator><creator>Ho, Tuan A.</creator><creator>Martin, Keith R.</creator><creator>McNaught, Andrew I.</creator><creator>Negi, Anil</creator><creator>Patel, Krishna</creator><creator>Russell, Richard A.</creator><creator>Shah, Ameet</creator><creator>Spry, Paul G.</creator><creator>Suzuki, Katsuyoshi</creator><creator>White, Edward T.</creator><creator>Wormald, Richard P.</creator><creator>Xing, Wen</creator><creator>Zeyen, Thierry G.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9148-2804</orcidid><orcidid>https://orcid.org/0000-0002-7772-5929</orcidid><orcidid>https://orcid.org/0000-0001-8754-3902</orcidid></search><sort><creationdate>20240801</creationdate><title>Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study</title><author>Rabiolo, Alessandro ; Montesano, Giovanni ; Crabb, David P. ; Garway-Heath, David F. ; Garway-Heath, David F. ; Crabb, David P. ; Bunce, Catey ; Lascaratos, Gerassimos ; Amalfitano, Francesca ; Anand, Nitin ; Azuara-Blanco, Augusto ; Bourne, Rupert R. ; Broadway, David C. ; Cunliffe, Ian A. ; Diamond, Jeremy P. ; Fraser, Scott G. ; Ho, Tuan A. ; Martin, Keith R. ; McNaught, Andrew I. ; Negi, Anil ; Patel, Krishna ; Russell, Richard A. ; Shah, Ameet ; Spry, Paul G. ; Suzuki, Katsuyoshi ; White, Edward T. ; Wormald, Richard P. ; Xing, Wen ; Zeyen, Thierry G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-878afa7d071858f6beadf0226b3a67628972c568dada1346d28599642c48a05d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Circadian Rhythm - physiology</topic><topic>Disease Progression</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Glaucoma, Open-Angle - drug therapy</topic><topic>Glaucoma, Open-Angle - physiopathology</topic><topic>Humans</topic><topic>Intraocular Pressure - physiology</topic><topic>Latanoprost - therapeutic use</topic><topic>Linear mixed models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ocular pulse amplitude</topic><topic>Risk factors</topic><topic>Tonometry, Ocular</topic><topic>United Kingdom</topic><topic>Vision Disorders - physiopathology</topic><topic>Visual field progression</topic><topic>Visual Field Tests</topic><topic>Visual Fields - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rabiolo, Alessandro</creatorcontrib><creatorcontrib>Montesano, Giovanni</creatorcontrib><creatorcontrib>Crabb, David P.</creatorcontrib><creatorcontrib>Garway-Heath, David F.</creatorcontrib><creatorcontrib>Garway-Heath, David F.</creatorcontrib><creatorcontrib>Crabb, David P.</creatorcontrib><creatorcontrib>Bunce, Catey</creatorcontrib><creatorcontrib>Lascaratos, Gerassimos</creatorcontrib><creatorcontrib>Amalfitano, Francesca</creatorcontrib><creatorcontrib>Anand, Nitin</creatorcontrib><creatorcontrib>Azuara-Blanco, Augusto</creatorcontrib><creatorcontrib>Bourne, Rupert R.</creatorcontrib><creatorcontrib>Broadway, David C.</creatorcontrib><creatorcontrib>Cunliffe, Ian A.</creatorcontrib><creatorcontrib>Diamond, Jeremy P.</creatorcontrib><creatorcontrib>Fraser, Scott G.</creatorcontrib><creatorcontrib>Ho, Tuan A.</creatorcontrib><creatorcontrib>Martin, Keith R.</creatorcontrib><creatorcontrib>McNaught, Andrew I.</creatorcontrib><creatorcontrib>Negi, Anil</creatorcontrib><creatorcontrib>Patel, Krishna</creatorcontrib><creatorcontrib>Russell, Richard A.</creatorcontrib><creatorcontrib>Shah, Ameet</creatorcontrib><creatorcontrib>Spry, Paul G.</creatorcontrib><creatorcontrib>Suzuki, Katsuyoshi</creatorcontrib><creatorcontrib>White, Edward T.</creatorcontrib><creatorcontrib>Wormald, Richard P.</creatorcontrib><creatorcontrib>Xing, Wen</creatorcontrib><creatorcontrib>Zeyen, Thierry G.</creatorcontrib><creatorcontrib>United Kingdom Glaucoma Treatment Study Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmology (Rochester, Minn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rabiolo, Alessandro</au><au>Montesano, Giovanni</au><au>Crabb, David P.</au><au>Garway-Heath, David F.</au><au>Garway-Heath, David F.</au><au>Crabb, David P.</au><au>Bunce, Catey</au><au>Lascaratos, Gerassimos</au><au>Amalfitano, Francesca</au><au>Anand, Nitin</au><au>Azuara-Blanco, Augusto</au><au>Bourne, Rupert R.</au><au>Broadway, David C.</au><au>Cunliffe, Ian A.</au><au>Diamond, Jeremy P.</au><au>Fraser, Scott G.</au><au>Ho, Tuan A.</au><au>Martin, Keith R.</au><au>McNaught, Andrew I.</au><au>Negi, Anil</au><au>Patel, Krishna</au><au>Russell, Richard A.</au><au>Shah, Ameet</au><au>Spry, Paul G.</au><au>Suzuki, Katsuyoshi</au><au>White, Edward T.</au><au>Wormald, Richard P.</au><au>Xing, Wen</au><au>Zeyen, Thierry G.</au><aucorp>United Kingdom Glaucoma Treatment Study Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study</atitle><jtitle>Ophthalmology (Rochester, Minn.)</jtitle><addtitle>Ophthalmology</addtitle><date>2024-08-01</date><risdate>2024</risdate><volume>131</volume><issue>8</issue><spage>902</spage><epage>913</epage><pages>902-913</pages><issn>0161-6420</issn><issn>1549-4713</issn><eissn>1549-4713</eissn><abstract>To investigate whether intraocular pressure (IOP) fluctuation is associated independently with the rate of visual field (VF) progression in the United Kingdom Glaucoma Treatment Study. Randomized, double-masked, placebo-controlled multicenter trial. Participants with ≥5 VFs (213 placebo, 217 treatment). Associations between IOP metrics and VF progression rates (mean deviation [MD] and five fastest locations) were assessed with linear mixed models. Fluctuation variables were mean Pascal ocular pulse amplitude (OPA), standard deviation (SD) of diurnal Goldmann IOP (diurnal fluctuation), and SD of Goldmann IOP at all visits (long-term fluctuation). Fluctuation values were normalized for mean IOP to make them independent from the mean IOP. Correlated nonfluctuation IOP metrics (baseline, peak, mean, supine, and peak phasing IOP) were combined with principal component analysis, and principal component 1 (PC1) was included as a covariate. Interactions between covariates and time from baseline modeled the effect of the variables on VF rates. Analyses were conducted separately in the two treatment arms. Associations between IOP fluctuation metrics and rates of MD and the five fastest test locations. In the placebo arm, only PC1 was associated significantly with the MD rate (estimate, –0.19 dB/year [standard error (SE), 0.04 dB/year]; P &lt; 0.001), whereas normalized IOP fluctuation metrics were not. No variable was associated significantly with MD rates in the treatment arm. For the fastest five locations in the placebo group, PC1 (estimate, –0.58 dB/year [SE, 0.16 dB/year]; P &lt; 0.001), central corneal thickness (estimate, 0.26 dB/year [SE, 0.10 dB/year] for 10 μm thicker; P = 0.01) and normalized OPA (estimate, –3.50 dB/year [SE, 1.04 dB/year]; P = 0.001) were associated with rates of progression; normalized diurnal and long-term IOP fluctuations were not. In the treatment group, only PC1 (estimate, –0.27 dB/year [SE, 0.12 dB/year]; P = 0.028) was associated with the rates of progression. No evidence supports that either diurnal or long-term IOP fluctuation, as measured in clinical practice, are independent factors for glaucoma progression; other aspects of IOP, including mean IOP and peak IOP, may be more informative. Ocular pulse amplitude may be an independent factor for faster glaucoma progression. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38354911</pmid><doi>10.1016/j.ophtha.2024.02.008</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-9148-2804</orcidid><orcidid>https://orcid.org/0000-0002-7772-5929</orcidid><orcidid>https://orcid.org/0000-0001-8754-3902</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0161-6420
ispartof Ophthalmology (Rochester, Minn.), 2024-08, Vol.131 (8), p.902-913
issn 0161-6420
1549-4713
1549-4713
language eng
recordid cdi_proquest_miscellaneous_2927214209
source MEDLINE; Elsevier ScienceDirect Journals
subjects Aged
Antihypertensive Agents - therapeutic use
Circadian Rhythm - physiology
Disease Progression
Double-Blind Method
Female
Glaucoma, Open-Angle - drug therapy
Glaucoma, Open-Angle - physiopathology
Humans
Intraocular Pressure - physiology
Latanoprost - therapeutic use
Linear mixed models
Male
Middle Aged
Ocular pulse amplitude
Risk factors
Tonometry, Ocular
United Kingdom
Vision Disorders - physiopathology
Visual field progression
Visual Field Tests
Visual Fields - physiology
title Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T11%3A31%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relationship%20between%20Intraocular%20Pressure%20Fluctuation%20and%20Visual%20Field%20Progression%20Rates%20in%20the%20United%20Kingdom%20Glaucoma%20Treatment%20Study&rft.jtitle=Ophthalmology%20(Rochester,%20Minn.)&rft.au=Rabiolo,%20Alessandro&rft.aucorp=United%20Kingdom%20Glaucoma%20Treatment%20Study%20Investigators&rft.date=2024-08-01&rft.volume=131&rft.issue=8&rft.spage=902&rft.epage=913&rft.pages=902-913&rft.issn=0161-6420&rft.eissn=1549-4713&rft_id=info:doi/10.1016/j.ophtha.2024.02.008&rft_dat=%3Cproquest_cross%3E2927214209%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2927214209&rft_id=info:pmid/38354911&rft_els_id=S0161642024001234&rfr_iscdi=true